Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Equity Investment Corp

Equity Investment Corp cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,333,446 shares of the medical equipment provider’s stock after selling 108,509 shares during the quarter. Zimmer Biomet comprises approximately 2.4% of Equity Investment Corp’s investment portfolio, making the stock its 12th biggest position. Equity Investment Corp’s holdings in Zimmer Biomet were worth $119,903,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Xponance LLC increased its stake in shares of Zimmer Biomet by 6.5% in the 4th quarter. Xponance LLC now owns 28,425 shares of the medical equipment provider’s stock worth $2,556,000 after acquiring an additional 1,738 shares during the last quarter. CSM Advisors LLC increased its stake in shares of Zimmer Biomet by 10.0% in the 4th quarter. CSM Advisors LLC now owns 7,483 shares of the medical equipment provider’s stock worth $672,000 after acquiring an additional 683 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Zimmer Biomet by 13.2% in the 4th quarter. Deutsche Bank AG now owns 769,702 shares of the medical equipment provider’s stock worth $69,212,000 after acquiring an additional 90,027 shares during the last quarter. Brandes Investment Partners LP increased its position in shares of Zimmer Biomet by 215.3% during the 4th quarter. Brandes Investment Partners LP now owns 48,863 shares of the medical equipment provider’s stock worth $4,394,000 after purchasing an additional 33,368 shares during the last quarter. Finally, LPL Financial LLC increased its position in shares of Zimmer Biomet by 5.6% during the 4th quarter. LPL Financial LLC now owns 136,383 shares of the medical equipment provider’s stock worth $12,264,000 after purchasing an additional 7,182 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.28% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ZBH shares. Stifel Nicolaus cut their price objective on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th. Leerink Partners started coverage on Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price objective for the company. Canaccord Genuity Group set a $83.00 price objective on Zimmer Biomet in a research report on Wednesday, April 29th. Citigroup cut their price objective on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. Finally, Robert W. Baird set a $92.00 price objective on Zimmer Biomet in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $102.70.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $87.26 on Friday. The business has a 50-day moving average of $87.61 and a 200 day moving average of $90.44. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The stock has a market capitalization of $16.88 billion, a price-to-earnings ratio of 22.67, a price-to-earnings-growth ratio of 2.04 and a beta of 0.47. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. During the same period last year, the business posted $1.81 EPS. Zimmer Biomet’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.